Breast cancer data analyzed by race/ethnic groups to identify differences in diagnosis, prognosis
the ONA take:
According to a new study published in the journal JAMA, researchers from Women's College Hospital in Toronto, Ontario, Canada, have found that race and ethnicity may play a role in the timing of breast cancer diagnosis and the prognosis of the woman's disease.
For the study, researchers sought to investigate whether biological differences in tumor aggressiveness affect differences in early-stage breast cancer diagnosis by ethnicity and race.
They identified 373,563 women diagnosed with stage 1 breast cancer from the Surveillance, Epidemiology and End Results (SEER) database between 2004 and 2011. Women were followed for an average of 40.6 months. Researchers then categorized those women based on race and ethnicity and assessed the biological aggressiveness of the tumors.
They also assessed timing of diagnosis and prognosis based on race/ethnic group. Results showed that Japanese women were more likely to be diagnosed with stage 1 breast cancer than non-Hispanic white women.
In addition, black and South Asian women were more likely to be diagnosed at a later stage than non-Hispanic white women, and black women were more likely to die from stage 1 disease than non-Hispanic white women and South Asian women. Black women were also more likely to die from small-sized tumors than non-Hispanic white women.
When analyzing biological differences in tumor aggressiveness, they found that black women with small-sized tumors were more likely to have triple-negative disease and to present with local and distant metastases than non-Hispanic white women. The researchers note that socioeconomic factors and access to health care may also play a role.
Race and ethnicity may play a role in the timing of breast cancer diagnosis and the prognosis of the woman's disease.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|